Skip to main content
Book Chapter

Biopharma 4.0 for Biologics Manufacturing Under Pandemic Constraints

  • Schmidt A
  • Hengelbrock A
  • Strube J
DOI: 10.1007/978-3-031-45669-5_10
N/ACitations
Citations of this article
2Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Biologics are the fastest growing molecular group in pharmaceutical therapies as supplying large most human-body like molecules with high efficacy at low doses and less side effects. Biopharma 4.0 relates to the fourth industrial revolution based on digitalization....

Cite

CITATION STYLE

APA

Schmidt, A., Hengelbrock, A., & Strube, J. (2023). Biopharma 4.0 for Biologics Manufacturing Under Pandemic Constraints (pp. 297–317). https://doi.org/10.1007/978-3-031-45669-5_10

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free